• TEL: 0086-13083697781

effect of darapladib on major coronary events after an

Get Price

We can supply you need effect of darapladib on major coronary events after an.

Darapladib - an overview ScienceDirect Topics

Darapladib markedly inhibited the plasma PAF-AH activity and reduced the lysoPC contents in coronary artery lesions. Concomitantly, darapladib treatment resulted in a significant decrease in the plaque area and necrotic core area and reduced medial destruction [84]. The effect of darapladib was also associated with a marked decrease in the Darapladib - an overview ScienceDirect TopicsDarapladib markedly inhibited the plasma PAF-AH activity and reduced the lysoPC contents in coronary artery lesions. Concomitantly, darapladib treatment resulted in a significant decrease in the plaque area and necrotic core area and reduced medial destruction [84]. The effect of darapladib was also associated with a marked decrease in the

Darapladib SB480848 CAS#356057-34-6 Lp-PLA2

Darapladib, also known as SB-480848, is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM, which is in Phase 3 trials. Recent studies showed that risk of major coronary events not reduced by darapladib therapy. In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of Darapladib for Suppressing Inflammation and Improving Dec 23, 2014 · The STABILITY trial demonstrated that darapladib failed to significantly reduce the primary endpoint of MACCE or its individual components of cardiovascular death, myocardial infarction, or stroke. There was a very modest reduction in the secondary endpoints of major coronary events and total coronary events. Commentary/Perspective ESC:Darapladib Doesn't Cut Major Coronary Events After No reduction in composite of coronary heart disease death, MI, or revascularization for MI

ESC:Darapladib Doesn't Cut Major Coronary Events After

No reduction in composite of coronary heart disease death, MI, or revascularization for MI Effect of Darapladib on Major Coronary Events After an Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome The SOLID-TIMI 52 Randomized Clinical Trial:Published in:JAMA, 312(10), 1006 - 1015. American Medical Association. ISSN 0098-7484. Author Effect of Darapladib on Major Coronary Events After an Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome The SOLID-TIMI 52 Randomized Clinical Trial:Published in:JAMA, 312(10), 1006 - 1015. American Medical Association. ISSN 0098-7484. Author

Effect of darapladib on major coronary events after an

Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme. Effect of darapladib on major coronary events after an acute coronary syndrome:the SOLID-TIMI 52 randomized clinical trial Author:O'Donoghue, Michelle L. Author:Braunwald, Eugene Author:White, Harvey D. Effect of darapladib on major coronary events after an Effect of darapladib on major coronary events after an acute coronary syndrome:the SOLID-TIMI 52 randomized clinical trial. Publikation:Bidrag til tidsskrift Tidsskriftartikel Forskning peer review Effect of darapladib on major coronary events after an OBJECTIVE:To evaluate the efficacy and safety of darapladib in patients after an acute coronary syndrome (ACS) event. DESIGN, SETTING, AND PARTICIPANTS:SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial that randomized 13,026 participants within 30 days of hospitalization with an ACS (non-ST-elevation or ST-elevation

Inhibiting inflammatory enzyme after heart attack does not

Aug 31, 2014 · Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. JAMA, 2014; DOI:10.1001/jama.2014.11061; Cite This Page:MLA; APA; Chicago; The JAMA Network Journals. "Inhibiting SOLID-TIMI 52 TIMI STUDY GROUPEffect of darapladib on major coronary events after an acute coronary syndrome:the SOLID-TIMI 52 randomized clinical trial. Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an Sharon Crugnale's research works Brigham and Women's performance reports and the utilization of guideline-based therapies in a large clinical trial population enrolled after an acute coronary syndrome:insights from the solid-timi 52 trial.

The Effect of Inhibition of Lp-PLA2 With Darapladib on

Jul 18, 2014 · The curves have a visual appearance of diverging after two years. Total coronary events were reduced with darapladib:14.9% versus 16.0%; HR 0.91 (0.84, 0.98), p=0.019. There was no difference in total mortality. The treatment effect for the primary endpoint was consistent in almost all prespecified subgroups. The changing face of atherosclerotic plaque inflammation3 White HD, Held C, Stewart R et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370:170211. 4 ODonoghue ML, Braunwald E, White HD et al. Effect of darapladib on major coronary events after an acute coronary syndrome:the SOLID-TIMI 52 randomized clinical trial. JAMA 2014; 312:100615. The changing face of atherosclerotic plaque inflammation3 White HD, Held C, Stewart R et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370:170211. 4 ODonoghue ML, Braunwald E, White HD et al. Effect of darapladib on major coronary events after an acute coronary syndrome:the SOLID-TIMI 52 randomized clinical trial. JAMA 2014; 312:100615.

(PDF) Effect of Darapladib on Major Coronary Events After

Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome

Get Price

We can supply you need effect of darapladib on major coronary events after an.